Rezolute announced on Mar. 24 that it has reached an agreement with the Food and Drug Administration (FDA) on a potential path forward for its hypoglycemia drug, ersodetug, following a failed Phase 3 trial.
The development is significant as it offers hope to patients with congenital hyperinsulinism, a rare condition characterized by low blood sugar. The FDA's willingness to further evaluate the data could lead to new treatment options in an area where there are limited therapies.
According to Rezolute CEO Nevan Charles Elam, "It’s an unusual outcome to have this level of engagement with FDA." Although the sunRIZE study did not meet its primary endpoint regarding hypoglycemia events, Rezolute presented biomarker evidence and consistent improvements in time spent in hypoglycemia compared to placebo during a recent Type B meeting with the agency. The company said that self-monitored blood glucose may have confounded results due to divergent behaviors between treatment groups.
The FDA acknowledged these challenges and encouraged Rezolute to submit study reports and analysis datasets for further evaluation. "We are extremely encouraged by the outcome of our meeting with FDA including the fact that, while acknowledging their feedback was preliminary, the agency did not dismiss sunRIZE outright on the basis of not meeting its primary endpoint," Elam said. He added that it is "very, very unusual" for a division of the agency to request access to raw data sets for independent analysis.
Julie Raskin, CEO of Congenital Hyperinsulinism International, also praised the collaboration: "As an attendee of the meeting, I was extremely impressed observing FDA and Rezolute working together with a common understanding of the profound burden congenital hyperinsulinism places on patients and caregivers..."
Ersodetug remains Rezolute's only clinical-stage asset. While another randomized controlled trial may still be required based on ongoing review by regulators, Elam said he believes continued engagement reflects recognition of visible clinical benefit.
